GLP-1 Improves Diastolic Function and Survival in Heart Failure with Preserved Ejection Fraction

Journal of Cardiovascular Translational Research
T Dung NguyenTorsten Doenst

Abstract

Heart failure with preserved ejection fraction (HFpEF) has emerged as a public health burden with currently no effective medication. We assessed the treatment effects of the incretin hormone glucagon-like peptide-1 (GLP-1) on cardiac metabolism and function in a model of HFpEF. Following aortic banding, rats developed HFpEF characterized by diastolic dysfunction, pulmonary congestion, and poor survival (38%). A 4-week GLP-1 treatment via osmotic pumps significantly improved survival (70%) and reduced left ventricular stiffness, diastolic dysfunction, and pulmonary congestion. Isolated heart perfusion revealed preserved cardiac glucose oxidation (GO) and a shift in cardiac substrate utilization towards GO. While GLP-1 may boost insulin secretion and responsiveness, the protective effects were not related to cardiac insulin action. GLP-1 improves diastolic function and survival in rats with HFpEF, which was associated with a cardiac substrate switch towards GO. The therapeutic role of GLP-1 in HFpEF is new and warrants further investigation.

References

Oct 16, 2002·Circulation·Heinrich Taegtmeyer
Sep 5, 2003·Basic Research in Cardiology·Ulrich Fischer-RasokatTorsten Doenst
Sep 23, 2003·The Thoracic and Cardiovascular Surgeon·V ZahaT Doenst
Jun 18, 2004·Annals of the New York Academy of Sciences·Heinrich TaegtmeyerMelissa van Arsdall
Jul 19, 2005·American Journal of Physiology. Heart and Circulatory Physiology·Lazaros A NikolaidisRichard P Shannon
Mar 7, 2006·Cell Metabolism·Daniel J Drucker
Oct 16, 2008·Cardiovascular Research·Marc van BilsenGer J van der Vusse
Feb 7, 2009·Journal of the American College of Cardiology·Leo TimmersImo E Hoefer
Jan 19, 2010·American Journal of Physiology. Heart and Circulatory Physiology·Mads HalbirkHenrik Wiggers
Feb 16, 2010·Journal of the American College of Cardiology·Walter J Paulus, Joris J M van Ballegoij
May 11, 2010·Current Opinion in Clinical Nutrition and Metabolic Care·Aslan T TurerMihai V Podgoreanu
Nov 22, 2011·Journal of Molecular and Cellular Cardiology·Andrea SchrepperTorsten Doenst
Sep 13, 2012·Heart Failure Reviews·Moritz OsterholtTorsten Doenst
Jan 25, 2013·The Thoracic and Cardiovascular Surgeon·Yasushige ShinguTorsten Doenst
Aug 31, 2013·Circulation Research·Torsten DoenstE Dale Abel
Oct 24, 2013·Cardiovascular Diabetology·Derek J HausenloyDerek M Yellon
Oct 20, 2014·Current Cardiology Reports·A Afşin Oktay, Sanjiv J Shah
Mar 19, 2015·Circulation. Heart Failure·William C Little, Barry A Borlaug
Apr 12, 2015·American Journal of Physiology. Heart and Circulatory Physiology·Sara LeiteAndré P Lourenço
Mar 5, 2016·Netherlands Heart Journal : Monthly Journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation·G ConceiçãoI Falcão-Pires
Jun 28, 2016·Cell Metabolism·Daniel J Drucker
Aug 3, 2016·JAMA : the Journal of the American Medical Association·Kenneth B MarguliesUNKNOWN NHLBI Heart Failure Clinical Research Network
Dec 14, 2016·The New England Journal of Medicine·Margaret M Redfield

❮ Previous
Next ❯

Citations

Aug 14, 2020·Advanced Drug Delivery Reviews·T Dung Nguyen, P Christian Schulze
Apr 13, 2021·Heart Failure Reviews·Marijana TadicCesare Cuspidi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.